Uncovering the spectrum of healthcare resource utilization and costs across moderate to severe asthma: high-cost subgroups and impact of biologics.

OBJECTIVES

The healthcare burden of moderate asthma is not as well studied as severe asthma. This study used 2019 US claims data to characterize patients in Global Initiative for Asthma (GINA) steps 3 to 5 (moderate to severe) during the first 90 days of 2019.

METHODS

Patient characteristics, healthcare resource utilization and costs were described for all patients and GINA groups. Patients in GINA 3 accounting for the top 10% and 20% of asthma-related total costs were also analyzed.

RESULTS

In the overall asthma population (N = 337 015), mean asthma-related healthcare cost per patient was $12 560; for GINA 3, 4 and 5, costs were $10 265, $12 923, and $22 601, respectively. For the GINA 3 top 10% and 20% cost subgroups, these expenditures were higher than for GINA 5 ($54 549 and $94 386, respectively), driven by outpatient and inpatient costs. The high-cost GINA 3 subgroups were older, more often female and had a higher comorbidity burden versus GINA 4 or 5. An exploratory analysis suggested that biologic initiation significantly increased costs in patients initially in GINA 3 (p < 0.0001), but significantly reduced costs in GINA 3 top 10% and 20% cost subgroups (both p < 0.01).

CONCLUSION

Results indicate patients receiving GINA 3 treatment can have a high disease burden and may benefit from treatment with a biologic.